July 2026– date –
-
Helus Pharma™’s Breakthrough-Designated Depression Drug HLP003 Completes 86% Enrollment in Phase 3 Trial, Topline Data Expected Q4 2026
PR Newswire Unknown Overview Helus Pharma™’s APPROACH Phase 3 trial for HLP003, an investigational adjunct therapy for major depressive disorder (MDD), has successfully completed over 86% of patient enrollment. HLP003 has received Breakt... -
ADC Therapeutics Completes Enrollment for LOTIS-7 Phase 1b Trial of Zynlonta-Glofitamab Combination, Reporting Interim 89.8% ORR in Relapsed/Refractory DLBCL Patients
BioPharm International Switzerland Overview ADC Therapeutics has completed patient enrollment for the Phase 1b LOTIS-7 trial, evaluating the combination of its CD19-targeted antibody-drug conjugate (ADC) Zynlonta with the bispecific anti... -
Focused Ultrasound BBB Opening Facilitates Limited LNP-modRNA Brain Delivery in Niemann-Pick Disease Type C Mouse Model but Fails to Induce Therapeutic Effect
bioRxiv Unknown Overview Efficient molecular therapeutic delivery to the central nervous system (CNS) remains a major barrier in neurogenetic disorders like Niemann-Pick Disease Type C (NPC). This preprint evaluated Focused ultrasound-me... -
Frontiers of Molecular and Material Design with Generative AI and Deep Learning: Accelerating Drug Discovery and Materials Informatics via Research Lists
GitHub Unknown Overview This GitHub repository provides a comprehensive list of recent reviews, evaluation metrics, and benchmarks related to molecular and material design using generative AI and deep learning. The list aims to compile c... -
Kowa’s Selective PPARα Modulator Pemafibrate Receives FDA Breakthrough Therapy Designation for Primary Biliary Cholangitis Treatment, Demonstrating Significant ALP Improvement in Phase II Data
Morningstar Japan Overview Japan's Kowa Company has announced that its selective PPARα modulator "K-808" (pemafibrate) has been granted Breakthrough Therapy designation by the U.S. FDA for the treatment of primary biliary cholangitis (PB... -
ADC Technology Evolves: Data-Driven Design from Antigen Selection to AI-Assisted Engineering Transforms Therapeutic Paradigm
MDPI Unknown Overview Antibody-drug conjugates (ADCs) have evolved into a mature therapeutic platform with exponentially increasing clinical relevance. This review highlights recent advances in ADC design and development, emphasizing the... -
EAACI 2026: Wave Life Sciences’ siRNA BW-20805 Shows 93-99% Attack Rate Reduction in Hereditary Angioedema Phase 2, with 60-83% Patients Remaining Attack-Free
EMJ Allergy & Immunology Unknown Overview At the EAACI 2026 conference, updated Phase 2 data for Wave Life Sciences' BW-20805, a plasma prekallikrein-targeting GalNAc-siRNA, revealed highly promising results in adult patients with heredi... -
Identifying Blood-Brain Barrier (BBB) Bottleneck: Nanomedicine Key to Overcoming Glioblastoma Brain Drug Delivery Challenges
Neuroscience News Unknown Overview The blood-brain barrier (BBB), a major obstacle to brain drug delivery, severely limits therapies for neurological disorders like glioblastoma. Recent research identified intracellular sorting after dru... -
McKinsey Report: Generative AI and Foundation Models Revolutionize Biopharma R&D Workflow, Accelerating Molecular Design and Antibody Engineering
McKinsey Unknown Overview A McKinsey report highlights that generative AI and foundation models are revolutionizing biopharma R&D workflows. These AI models design novel molecular structures, experimental hypotheses, and synthetic pa... -
AI-Driven JAM Platform Designs Molecular Binders Beyond GPCR Antibody Generation: Achieves High Hit Rates for CXCR7 and Claudin-4 Targets, AI-Discovered Drugs Advance to Phase IIa
Pharma Focus Asia Unknown Overview The AI-driven JAM platform has surpassed traditional GPCR antibody generation methods, predicting previously overlooked molecular binding interactions. JAM computationally designed binders for multi-tra...
